# Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

> clinical trial · VERIFIED · 2026-08-21

Status: RECRUITING · Sponsor: The First Affiliated Hospital of Xiamen University · Condition: DLBCL - Diffuse Large B Cell Lymphoma

- Company: The First Affiliated Hospital of Xiamen University
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07778212

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.